Comparative Pharmacology
Head-to-head clinical analysis: STATROL versus SYNALAR HP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STATROL versus SYNALAR HP.
STATROL vs SYNALAR-HP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
Corticosteroid that binds to glucocorticoid receptors, altering gene expression to inhibit inflammatory mediators (e.g., prostaglandins, leukotrienes) and suppress immune cell activity.
10 mg orally once daily
Apply a thin film to the affected area once or twice daily for up to 2 weeks, using the lowest effective dose. Not for use under occlusive dressings or on large areas.
None Documented
None Documented
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life: 2-3 hours (topical) due to rapid clearance; systemic half-life: 1-2 hours
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Renal: 90% as metabolites; biliary/fecal: minimal (<5%)
Category C
Category C
Otic Antibiotic/Corticosteroid
Corticosteroid